查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1371913

全球自動注射器市場，到 2030 年的預測：按類型、給藥途徑、治療方法、分子類型、配銷通路、最終用戶和地區進行的全球分析

Auto-Injectors Market Forecasts to 2030 - Global Analysis By Type, Route of Administration, Therapy, Type of Molecule, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球自動注射器市場規模為 20.3 億美元，預計到 2030 年將達到 79.4 億美元，預測期內年複合成長率為 21.5%。

自動注射器是一種帶有彈簧針頭的注射器，預先裝有藥物。當注射器以滑動方式推入體內時，系統會啟動並給藥準確量的藥物。自動注射器通常用於偏頭痛患者自我給藥腎上腺素以及醫療和緊急治療。

根據美國國家健康訪問調查 (NHIS)，近 52% 的美國成年人被診斷出患有至少一種慢性病，包括氣喘、糖尿病和高血壓。

慢性病增加

隨著糖尿病、類風濕性關節炎和多發性硬化症等慢性疾病變得越來越普遍，自動注射器的需求也增加。自動注射器提供了一種安全可靠的方法來給藥這些藥物，通常會定期注射來治療這些疾病。例如，國際糖尿病聯盟（IDF）估計，2021年全球有5.37億人罹患糖尿病，預計未來這一數字將迅速增加。糖尿病年度直接導致 150 萬人死亡，其中大多數生活在低收入和中等收入國家。此外，由於已開發經濟體和新興經濟體的預防性醫療保健的重要性日益增加，自動注射器市場統計數據預計將增加。

替代藥物輸送的潛力

傳統上，注射藥物是用注射器給藥的，而且很痛苦。因此，其他給藥方法，如口服、鼻腔和局部，越來越受到患者和醫療保健專業人員的關注。此外，技術的進步導致了無針注射器的發展，使得許多藥物能夠頻繁地給藥生長激素缺乏、類風濕性關節炎和糖尿病等疾病。因此，患有這些疾病的患者可能會對重複注射產生針頭恐懼症，促使他們改用替代藥物傳遞方法。

擴大轉向家庭治療

居家醫療正引起全世界的關注。這是由於醫療技術的進步、與醫院治療相比節省的大量資金以及患者偏好的變化。此外，自動注射器都開拓了技術進步，例如更容易操作和給藥的視聽提示、更好的幫助的連接性以及減少給藥頻率的大容量給藥裝置。 ，正在支持自動注射器的採用在家庭護理環境中，帶來了市場機會。

法規挑戰

嚴格的法規要求可能是一項重大挑戰，尤其是在醫療保健和製藥領域。法規變化、合規問題和冗長的核准流程可能會延遲我們產品的推出。因此，成本可能會增加並阻礙市場進入和成長。

COVID-19 的影響

儘管 COVID-19 的爆發擾亂了許多醫療保健業務，但自動注射器市場仍在經歷強勁的收益成長。市場需求的進一步促進因素是 COVID-19 患者各種呼吸道併發症的發生率不斷上升。自動注射器是一種自我給藥的藥物裝置，其中包含用於治療各種疾病的各種藥物，包括類風濕性關節炎、糖尿病等。此外，自動注射器有助於定期給藥，這在 COVID-19 大流行期間非常普及，當時醫療設施擠滿了新冠肺炎 (COVID-19) 患者。

類風濕性關節炎領域預計在預測期內將是最大的。

預計類風濕性關節炎將在預測期內佔據重要的市場佔有率。類風濕性關節炎(RA) 是一種自體免疫疾病，當人體的免疫系統攻擊關節、發炎並導致關節和周圍組織腫脹和疼痛時，就會發生這種疾病。女性比男性更容易患關節炎，並且主要罹患老年人。例如，根據聯合國《2020年世界人口預測》報告，目前全球65歲以上人口有7.27億，預計到2050年這數字將增加一倍以上。隨著老年人關節炎患病的上升，該市場預計在預測期內將擴大。

預計家庭護理領域在預測期內的年複合成長率最高。

預計家庭護理領域在預測期內將經歷最高的年複合成長率。由於對家庭醫療服務的需求不斷成長，自動注射器的使用預計會增加。許多藥物，包括 DMARD、生物製藥和疫苗，都可以使用這些設備進行給藥。此外，居家醫療環境中對自動注射器的需求。

佔比最高的地區

預計在預測期內，北美將佔據拋棄式自動注射器的最大市場佔有率。該地區的市場將受到技術先進產品的早期採用和產品核可以及慢性病患病患病上升等要素的推動。此外，由於技術進步、新參與企業的增加以及先進產品的快速採用，美國市場正在成長。因此，由於上述要素，北美地區預計將出現成長。

複合年複合成長率最高的地區

由於印度、中國、日本、新加坡和澳洲等國家糖尿病和食物過敏引起的過敏反應盛行率患病等要素，預計亞太地區將以最高的年複合成長率成長。糖尿病是許多亞洲國家的一個主要健康問題。因此，胰島素自動注射器的使用增加，以幫助糖尿病患者有效管理病情。由於上述要素，亞太地區自動注射器市場具有巨大的成長潛力。

免費客製化服務

訂閱此報告的客戶可以利用以下免費自訂選項之一：

  • 公司簡介
    • 其他市場公司的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究來源
    • 主要研究來源
    • 二次研究來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球自動注射器市場：按類型

  • 拋棄式的
  • 可重複使用的
    • 預充式自動注射器
    • 空自動注射器

第6章 全球自動注射器市場：依給藥途徑

  • 皮下的
  • 肌肉注射

第7章 全球自動注射器市場：依治療方法

  • 過敏反應
  • 氣喘
  • 糖尿病
  • 荷爾蒙治療
  • 偏頭痛
  • 多發性硬化症
  • 腫瘤學
  • 類風濕性關節炎
  • 其他治療方法

第8章 全球汽車注射器市場：依分子類型

  • 單株抗體
  • 胜肽
  • 蛋白質
  • 低分子

第9章 全球自動注射器市場：依配銷通路

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第10章 全球自動注射器市場：依最終用戶分類

  • 居家醫療環境
  • 醫院/診所
  • 門診治療

第11章全球自動注射器市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東/非洲

第12章進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章公司簡介

  • AbbVie Inc
  • Amgen Inc.
  • Antares Pharma
  • Bayer AG
  • Becton, Dickinson and Company
  • Biogen
  • Eli Lilly and Company
  • F. Hoffmann La Roche Ltd.
  • GlaxoSmithKline plc
  • Halozyme Therapeutics Inc.
  • Johnson & Johnson
  • medmix Ltd.
  • Merck KGaA
  • Owen Mumford Ltd.
  • Pfizer Inc.
  • Recipharm AB
  • Teva Pharmaceutical
  • Ypsomed
Product Code: SMRC23970

According to Stratistics MRC, the Global Auto-Injectors Market is accounted for $2.03 billion in 2023 and is expected to reach $7.94 billion by 2030 growing at a CAGR of 21.5% during the forecast period. An auto-injector is a syringe with a needle that has been pre-charged with a dosage of drugs and is spring-charged. When a sliding motion is used to press the device into the body, the system activates and delivers a precise dosage of a medication. The self-administration of epinephrine by migraineurs or for medical and emergency treatments is frequently done with the aid of auto-injectors.

According to the National Health Interview Survey (NHIS), nearly 52% of the adult population in the US is diagnosed with at least one chronic condition, such as asthma, diabetes, and hypertension.

Market Dynamics:

Driver:

Increasing prevalence of chronic diseases

The demand for auto-injectors has also increased as chronic diseases like diabetes, rheumatoid arthritis, and multiple sclerosis are becoming more common. Auto-injectors provide a secure and reliable way to administer these medications, which are frequently injected regularly to treat these conditions. For instance, The International Diabetes Federation (IDF) estimates that 537 million people worldwide had diabetes in 2021, and that number is expected to rise sharply in the years to come. Since the majority live in low- and middle-income countries, diabetes directly causes 1.5 million deaths annually. Moreover, market statistics for auto-injectors will increase due to the rising significance of preventive care in both developed and developing economies.

Restraint:

Availability of alternative modes of drug delivery

Traditionally, injectable medications have been delivered with a syringe and are painful to receive. This is why other administration methods like oral, nasal, and topical routes are gaining more attention from both patients and healthcare professionals. Additionally, owing to technological developments, needle-free injectors have been created, and a lot of drugs are administered frequently for conditions like growth hormone deficiency, rheumatoid arthritis, and diabetes, among others. As a result, patients with these conditions may develop needle phobia as a result of repeated injections, which would encourage them to switch to alternative drug delivery methods.

Opportunity:

Rising shift of therapy to home settings

Home care settings are receiving more attention worldwide. This is supported by improvements in medical technology, significant financial savings over hospital-based treatments, and changing patient preferences. Additionally, the development of auto-injectors with technological advancements like audio-visual cues for easy handling and administration, connectivity for better assistance, and large dose and volume devices for less frequent drug administration are all supporting the adoption of auto-injectors in home care settings, which consequently offers opportunities in the market.

Threat:

Regulatory challenges

Stringent regulatory requirements, especially in the healthcare and pharmaceutical sectors, can pose significant challenges. Changes in regulations, compliance issues, and lengthy approval processes can delay product launches. As a result, it increases costs, which might impede market entry and growth.

COVID-19 Impact:

The COVID-19 outbreak has interfered with a number of healthcare operations, but the auto-injector market is still experiencing strong revenue growth. An additional driver of market demand is the rising incidence rate of various respiratory complications among COVID-19 patients. Auto-injectors are self-administration drug devices that contain a range of medications for the treatment of various illnesses, including rheumatoid arthritis, diabetes, and others. Additionally, auto-injectors aid in the administration of a regular dose of medication, which became very popular during the COVID-19 pandemic when healthcare facilities were overrun with COVID patients.

The rheumatoid arthritis segment is expected to be the largest during the forecast period

Over the forecast period, rheumatoid arthritis is anticipated to hold a sizable market share. An autoimmune condition called rheumatoid arthritis (RA) occurs when the body's immune system attacks the joints, inflaming the synovium and resulting in swelling and pain in the joints and the surrounding tissues. Women are more likely to have arthritis than men, and it primarily affects the elderly. For instance, According to the United Nations World Population Prospects 2020 report, there are currently 727 million people in the world who are 65 or older, and by the year 2050, this number is projected to more than double. As the prevalence of arthritis among the elderly population rises, this market segment will expand over the forecast period.

The homecare settings segment is expected to have the highest CAGR during the forecast period

During the anticipated timeframe, the segment for homecare settings is predicted to have the highest CAGR. The use of auto-injectors is anticipated to rise in response to the rising demand for healthcare services provided at home. Numerous medications, including DMARDs, biologics, and vaccines, can be administered using these devices. Moreover, the demand for auto-injectors in homecare settings will therefore be driven by the growing sophistication of healthcare infrastructure and accessibility, which is assisting in the market's expansion.

Region with largest share:

Throughout the forecast period, North America is anticipated to account for the largest market share for disposable auto-injectors. The market in the region is boosted by factors like early adoption of technologically advanced products and product approvals, as well as an increase in the prevalence of chronic diseases. In addition, the United States market is growing as a result of rising technological advancements, increased entry of new players, and quick adoption of advanced products. The North American region is therefore anticipated to experience growth as a result of the aforementioned factors.

Region with highest CAGR:

Due to factors like the rising prevalence of diabetes and anaphylaxis brought on by food allergies in nations like India, China, Japan, Singapore, and Australia, Asia Pacific is predicted to grow at the highest CAGR. In numerous Asian nations, diabetes is a major health concern. As a result, the use of insulin auto-injectors has increased to assist people with diabetes in effectively managing their condition. Due to the aforementioned factors, the Asia-Pacific region offers significant potential for growth in the auto-injector market.

Key players in the market:

Some of the key players in Auto-Injectors Market include: AbbVie Inc, Amgen Inc., Antares Pharma, Bayer AG, Becton, Dickinson and Company, Biogen, Eli Lilly and Company, F. Hoffmann La Roche Ltd., GlaxoSmithKline plc, Halozyme Therapeutics Inc., Johnson & Johnson, medmix Ltd., Merck KGaA, Owen Mumford Ltd., Pfizer Inc., Recipharm AB, Teva Pharmaceutical and Ypsomed.

Key Developments:

In October 2023, AbbVie announced that it has exercised its exclusive right and completed the acquisition of Mitokinin, a discovery-stage biotechnology company developing a potentially first-in-class disease-modifying treatment for Parkinson's Disease (PD). Mitokinin's lead compound, a selective PINK1 activator, is designed to address mitochondrial dysfunction that is believed to be a major contributing factor to Parkinson's disease pathogenesis and progression.

In October 2023, Amgen announced that it has completed its acquisition of Horizon Therapeutics plc for $116.50 per share in cash, representing a transaction equity value of approximately $27.8 billion.

Types Covered:

  • Disposable
  • Reusable

Route of Administration Covered:

  • Subcutaneous
  • Intramuscular

Therapies Covered:

  • Anaphylaxis
  • Asthma
  • Diabetes
  • Hormone Therapy
  • Migraine
  • Multiple Sclerosis
  • Oncology
  • Rheumatoid Arthritis
  • Other Therapies

Type of Molecules Covered:

  • Monoclonal Antibody
  • Peptide
  • Protein
  • Small Molecule

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

End Users Covered:

  • Home Care Settings
  • Hospitals & Clinics
  • Ambulatory Care Settings

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Auto-Injectors Market, By Type

  • 5.1 Introduction
  • 5.2 Disposable
  • 5.3 Reusable
    • 5.3.1 Prefilled Auto-injectors
    • 5.3.2 Empty Auto-injectors

6 Global Auto-Injectors Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Subcutaneous
  • 6.3 Intramuscular

7 Global Auto-Injectors Market, By Therapy

  • 7.1 Introduction
  • 7.2 Anaphylaxis
  • 7.3 Asthma
  • 7.4 Diabetes
  • 7.5 Hormone Therapy
  • 7.6 Migraine
  • 7.7 Multiple Sclerosis
  • 7.8 Oncology
  • 7.9 Rheumatoid Arthritis
  • 7.10 Other Therapies

8 Global Auto-Injectors Market, By Type of Molecule

  • 8.1 Introduction
  • 8.2 Monoclonal Antibody
  • 8.3 Peptide
  • 8.4 Protein
  • 8.5 Small Molecule

9 Global Auto-Injectors Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Hospital Pharmacies
  • 9.3 Retail Pharmacies
  • 9.4 Online Pharmacies

10 Global Auto-Injectors Market, By End User

  • 10.1 Introduction
  • 10.2 Home Care Settings
  • 10.3 Hospitals & Clinics
  • 10.4 Ambulatory Care Settings

11 Global Auto-Injectors Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 AbbVie Inc
  • 13.2 Amgen Inc.
  • 13.3 Antares Pharma
  • 13.4 Bayer AG
  • 13.5 Becton, Dickinson and Company
  • 13.6 Biogen
  • 13.7 Eli Lilly and Company
  • 13.8 F. Hoffmann La Roche Ltd.
  • 13.9 GlaxoSmithKline plc
  • 13.10 Halozyme Therapeutics Inc.
  • 13.11 Johnson & Johnson
  • 13.12 medmix Ltd.
  • 13.13 Merck KGaA
  • 13.14 Owen Mumford Ltd.
  • 13.15 Pfizer Inc.
  • 13.16 Recipharm AB
  • 13.17 Teva Pharmaceutical
  • 13.18 Ypsomed

List of Tables

  • Table 1 Global Auto-Injectors Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Auto-Injectors Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Auto-Injectors Market Outlook, By Disposable (2021-2030) ($MN)
  • Table 4 Global Auto-Injectors Market Outlook, By Reusable (2021-2030) ($MN)
  • Table 5 Global Auto-Injectors Market Outlook, By Prefilled Auto-injectors (2021-2030) ($MN)
  • Table 6 Global Auto-Injectors Market Outlook, By Empty Auto-injectors (2021-2030) ($MN)
  • Table 7 Global Auto-Injectors Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 8 Global Auto-Injectors Market Outlook, By Subcutaneous (2021-2030) ($MN)
  • Table 9 Global Auto-Injectors Market Outlook, By Intramuscular (2021-2030) ($MN)
  • Table 10 Global Auto-Injectors Market Outlook, By Therapy (2021-2030) ($MN)
  • Table 11 Global Auto-Injectors Market Outlook, By Anaphylaxis (2021-2030) ($MN)
  • Table 12 Global Auto-Injectors Market Outlook, By Asthma (2021-2030) ($MN)
  • Table 13 Global Auto-Injectors Market Outlook, By Diabetes (2021-2030) ($MN)
  • Table 14 Global Auto-Injectors Market Outlook, By Hormone Therapy (2021-2030) ($MN)
  • Table 15 Global Auto-Injectors Market Outlook, By Migraine (2021-2030) ($MN)
  • Table 16 Global Auto-Injectors Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
  • Table 17 Global Auto-Injectors Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 18 Global Auto-Injectors Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
  • Table 19 Global Auto-Injectors Market Outlook, By Other Therapies (2021-2030) ($MN)
  • Table 20 Global Auto-Injectors Market Outlook, By Type of Molecule (2021-2030) ($MN)
  • Table 21 Global Auto-Injectors Market Outlook, By Monoclonal Antibody (2021-2030) ($MN)
  • Table 22 Global Auto-Injectors Market Outlook, By Peptide (2021-2030) ($MN)
  • Table 23 Global Auto-Injectors Market Outlook, By Protein (2021-2030) ($MN)
  • Table 24 Global Auto-Injectors Market Outlook, By Small Molecule (2021-2030) ($MN)
  • Table 25 Global Auto-Injectors Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 26 Global Auto-Injectors Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 27 Global Auto-Injectors Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 28 Global Auto-Injectors Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 29 Global Auto-Injectors Market Outlook, By End User (2021-2030) ($MN)
  • Table 30 Global Auto-Injectors Market Outlook, By Home Care Settings (2021-2030) ($MN)
  • Table 31 Global Auto-Injectors Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 32 Global Auto-Injectors Market Outlook, By Ambulatory Care Settings (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.